Don't put all your eggs into one platform of vaccine development.
News & Analysis: Translate Bio, Inc.
If coronavirus vaccine development efforts are a race, then pharmaceutical companies will need to hurdle more than clinical trials to be successful.
The clinical-stage vaccine developer, which is working on a COVID-19 vaccine candidate, announced it's selling more shares to the public.
Major market benchmarks settled for modest gains on Tuesday.
The company's collaboration with Sanofi is shifting into a higher gear.
Biotech and big pharma are putting vaccines using messenger RNA to the coronavirus test.
Translate Bio's messenger RNA technology will make the development process faster than the traditional methods.
Unfilled promises by biotechs can lead to broken hearts for investors.
The company announced a stock offering to raise cash, but today's drop could've been much worse.